Working… Menu

PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03927261
Recruitment Status : Recruiting
First Posted : April 25, 2019
Last Update Posted : December 4, 2020
Precigen, Inc
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Brief Summary:
This study is to determine the safety and best dose of PRGN-3006 T Cells

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Acute Myeloid Leukemia Drug: PRGN-3006 T Cells Phase 1

Detailed Description:

This is a single center, nonrandomized, investigator-initiated Phase 1/1b safety and tolerability study. The safety and tolerability of PRGN-3006 T cells will be assessed following intravenous administration of escalating doses in patients with relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndromes (MDS).

This study will enroll in two phases: an initial dose escalation phase followed by a dose expansion phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome
Actual Study Start Date : May 20, 2019
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : May 1, 2025

Arm Intervention/treatment
Experimental: Dose Escalation and Dose Expansion of PRGN-3006
Participants will be treated in dose escalation phase to identify the safety and maximum tolerated dose (MTD) of PRGN-3006.
Drug: PRGN-3006 T Cells
Participants will receive a single intravenous (IV) administration of PRGN-3006 T Cells, and will be monitored for safety in the clinic for at least 7 days following infusion, and for safety, efficacy and correlative endpoints up to 12 months following infusion.

Primary Outcome Measures :
  1. Number of Participants who Experience Dose Limiting Toxicities (DLTs) [ Time Frame: Up to Day 42 ]

    A dose limiting toxicity (DLT) is any of the following and is determined by the investigator to be related to study drug:

    • Aplastic bone marrow, defined by marrow cellularity <5% at Day 28 in the absence of residual disease and confirmed at Day 42.
    • Treatment-emergent CRS of Grade 4 that does not resolve to Grade ≤2 within 72 hours, despite optimal treatment;
    • Treatment-emergent CRS of Grade 3 that does not resolve to Grade ≤2 within 2 weeks, despite optimal treatment;
    • Treatment-related Grade 4-5 allergic reactions
    • Treatment-related non-reversible Grade 3 (< 14 days), or any Grade 4-5 autoimmune reactions related to the study cell infusion.
    • Central neurologic toxicity Grade ≥3 lasting more than 14 days
    • Grade 5 Cytokine Release Syndrome (CRS)
    • Tumor Lysis Syndrome ≥ IV (Cairo and Bishop, 2004[2]) that does not resolve within 7 days

  2. Number of Participants who Experience Treatment Related Adverse Events (AEs) [ Time Frame: Up to 12 months post treatment ]
    Systemic toxicity in general and hematologic toxicity in specific will be assessed through the capture of AEs at each study visit and through laboratory assessments throughout the study. The severity of the AEs will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 scale.

Secondary Outcome Measures :
  1. Disease Progression in AML Participants [ Time Frame: Up to 15 years ]
    Proportion of AML patients achieving partial response (PR), complete response (CR), and/or morphologic leukemia free state (MLFS) by ELN Response Criteria in AML. CRh (complete PRGN-3006 T cells in patients with AML/MDS remission with partial hematological recovery) will also be captured, defined as <5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts

  2. Disease Response in MDS Patients [ Time Frame: Up to 15 years ]
    Proportion of MDS patients achieving a response (CR, PR or Marrow CR) as defined in International Working Group (IWG) 2006 Criteria.

  3. Rate of Absolute Neutrophil Count Recovery [ Time Frame: Day 28 ]
    Rate of Absolute Neutrophil count recovery (>0.5 x 10^9/L)

  4. Absolute Lymphocyte Count (ALC) [ Time Frame: Baseline ]
    ALC including CD4/CD8 subsets by flow cytometry at baseline (at apheresis) in patients who have successful versus failed PRGN-3006 production.

  5. Number of PRGN-3006 T Cells [ Time Frame: Up to 12 months post treatment ]
    Number of PRGN-3006 T Cells present in patients treated with PRGN-3006

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must be diagnosed with either relapsed or refractory AML or higher risk MDS
  • Absolute lymphocyte count ≥ 0.2 k/μL.
  • Karnofsky performance status score ≥60%.
  • Life expectancy ≥ 12 weeks from the time of enrollment.
  • Pretreatment calculated or measured creatinine clearance (absolute value) of ≥ 40 mL/minute or Cr > 2x upper limit of normal (ULN).
  • Serum bilirubin ≤ 2.0 mg/dL or total bilirubin ≤ 3.0 x IULN with direct bilirubin within normal range in participants with well documented Gilbert's syndrome or hemolysis or who require regular blood transfusions
  • Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 3.0 x IULN.
  • Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) > 45%.
  • Participant does not require supplemental oxygen or mechanical ventilation AND has an oxygen saturation by pulse oximetry of ≥ 92% or higher on room air.
  • Negative serum pregnancy test. Note: Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for at least 1 year following study treatment (T cell infusion); should a woman participant or female partner of a male participant become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.
  • Participant has a matched bone marrow donor and is otherwise able to receive a bone marrow transplant (dose escalation part only)
  • Participants who have undergone allo-SCT are eligible if they are at least 3 months post SCT, have relapsed AML/MDS as defined above, are not on treatment or prophylaxis for GVHD for at least 6 weeks before administration of CAR T cells, and have no active GVHD.
  • All participants must have the ability to understand and willingness to sign a written informed consent.

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.
  • Known central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation; participants with a history of CNS disease that have been effectively treated to complete remission ( i.e. no blasts in cerebrospinal fluid [CSF] by cytology and flow cytometry) will be eligible.
  • Prior treatment with investigational CAR T therapy for any disease.
  • Participants enrolled in another investigational therapy protocol for their disease within 14 days or 5 half-lives of enrollment, whichever is shorter.
  • Ongoing uncontrolled serious infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements.
  • Human immunodeficiency virus (HIV) seropositivity, or active hepatitis B or C infection based on testing performed within 28 days of enrollment.
  • Participants requiring agents other than hydroxyurea to control blast counts within 14 days of study enrollment.
  • Participants with presence of other active malignancy within 1 year of study entry;
  • Participants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.
  • Pregnant and lactating women are excluded from this study
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab (anti-EGFR).
  • Active autoimmune disease requiring systemic immunosuppressive therapy (i.e. >10mg of prednisone daily or equivalent).
  • Participant, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03927261

Layout table for location information
United States, Florida
H Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
Contact: Justin Uthuppan    813-745-8164   
Principal Investigator: David A Sallman, MD         
Principal Investigator: Nelli Bejanyan, MD         
Sub-Investigator: Rami Komrokji, MD         
Sub-Investigator: Jeffrey Lancet, MD         
Sub-Investigator: Kathy McGraw, PhD         
Sub-Investigator: Eric Padron, MD         
Sub-Investigator: Kendra Sweet, MD         
Sub-Investigator: Marco Davilla, MD, PhD         
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc
Layout table for investigator information
Principal Investigator: David A Sallman, MD H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator: Nelli Bejanyan, MD Moffitt Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute Identifier: NCT03927261    
Other Study ID Numbers: MCC-19862
First Posted: April 25, 2019    Key Record Dates
Last Update Posted: December 4, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions